Concepedia

Immune Checkpoint Inhibitor Use Near the End of Life Is Associated With Poor Performance Status, Lower Hospice Enrollment, and Dying in the Hospital

Chad Glisch, Yuya Hagiwara, Stephanie Gilbertson‐White, Yubo Gao

American Journal of Hospice and Palliative Medicine® · 2019 · 45 citations · 20 references

DOI

Abstract

Immune checkpoint inhibitor use in the last 30 days of life is common and associated with poor performance status, lower hospice enrollment, and dying in the hospital.

References

20

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

Jennifer S. Temel, Joseph A. Greer, Alona Muzikansky et al. · New England Journal of Medicine · 2010 · 7.2K citations

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

Shumei Kato, Aaron M. Goodman, Vighnesh Walavalkar et al. · Clinical Cancer Research · 2017 · 837 citations · Full text

Chemotherapy Use, Performance Status, and Quality of Life at the End of Life

Holly G. Prigerson, Yuhua Bao, Manish A. Shah et al. · JAMA Oncology · 2015 · 633 citations · Full text

Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study

Alexi A. Wright, B. Zhang, Nancy L. Keating et al. · BMJ · 2014 · 334 citations · Full text

Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer

Adrienne M. Gilligan, David S. Alberts, Denise J. Roe et al. · The American Journal of Medicine · 2018 · 225 citations

, , +13